Small activating RNAs (saRNAs) targeting MAS1, delivered by an amphiphilic dendrimer (AD) vector, enhance MAS1 expression and counteract the angiotensin II pathway in cancer cells, leading to significantly suppressed tumorigenesis and inhibited tumor progression. The gene discussed is MAS1; the disease is neoplasm.